BLLN Nasdaq Services-Medical Laboratories Financials FY2023βFY2025
BillionToOne, Inc. had $305M of revenue in fiscal 2025, up 100.0% on the year before.
Last close Β· Oct 23, 2026
$107.77
2.0%Hi! I read BillionToOne, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+100.0%
Yes. Sales grew 100.0% last year.
Does it make a profit?
2.4%
A little. It keeps 2.4% of every sale as profit.
Does profit turn into cash?
5.2%
Partly. 5.2% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
103.6x
One share costs 103.6 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days BillionToOne, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 6, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Dec 9, 2025 | Q3 '25 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· BillionToOne, Inc. had $305M of revenue in fiscal 2025, up 100.0% on the year before. Its operating margin was 5.3%, up 36.2Β pts: of every 100 in sales, about 5 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· BillionToOne, Inc. made $7.5M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $15.7M in fiscal 2025, 5.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· BillionToOne, Inc. returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 110.6%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $3.2M and sold $45.2M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$3.2M
6 insiders
Sold, 12 months
$45.2M
6 insiders
Of sales under plans
100%
$45.2M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | John Roderick ten BoschSVP of Laboratory Operations | Sold plan | 1,417 | $105.15 | $0.1M | Form 4 |
| Oct 5, 2026 | David TsaoChief Technology Officer, Director | Sold plan | 20,000 | $108.15 | $2.2M | Form 4 |
| Sep 28, 2026 | Oguzhan AtayChairman and CEO, Director | Sold plan | 10,999 | $120.64 | $1.3M | Form 4 |
| Sep 24, 2026 | John Roderick ten BoschSVP of Laboratory Operations | Sold plan | 1,416 | $120.00 | $0.2M | Form 4 |
| Sep 24, 2026 | David TsaoChief Technology Officer, Director | Sold plan | 3,333 | $125.00 | $0.4M | Form 4 |
| Sep 21, 2026 | John Roderick ten BoschSVP of Laboratory Operations | Sold plan | 1,416 | $106.61 | $0.2M | Form 4 |
| Sep 17, 2026 | Thomas P. LynchSee Remarks | Sold plan | 35,112 | $110.33 | $3.9M | Form 4 |
| Sep 14, 2026 | Oguzhan AtayChairman and CEO, Director | Sold plan | 27,665 | $100.10 | $2.8M | Form 4 |
| Sep 9, 2026 | David TsaoChief Technology Officer, Director | Sold plan | 20,000 | $98.77 | $2.0M | Form 4 |
| Sep 9, 2026 | John Roderick ten BoschSVP of Laboratory Operations | Sold plan | 1,416 | $97.54 | $0.1M | Form 4 |
| Sep 8, 2026 | Thomas P. LynchSee Remarks | Sold plan | 20,000 | $99.99 | $2.0M | Form 4 |
| Aug 25, 2026 | David TsaoChief Technology Officer, Director | Sold plan | 10,000 | $100.00 | $1.0M | Form 4 |
| Aug 25, 2026 | John Roderick ten BoschSVP of Laboratory Operations | Sold plan | 1,417 | $100.00 | $0.1M | Form 4 |
| Aug 10, 2026 | David TsaoChief Technology Officer, Director | Sold plan | 10,000 | $92.86 | $0.9M | Form 4 |
| Aug 10, 2026 | John Roderick ten BoschSVP of Laboratory Operations | Sold plan | 1,417 | $92.86 | $0.1M | Form 4 |
| Aug 5, 2026 | Oguzhan AtayChairman and CEO, Director | Sold plan | 15,539 | $150.03 | $2.3M | Form 4 |
| Aug 3, 2026 | Oguzhan AtayChairman and CEO, Director | Sold plan | 38,577 | $137.03 | $5.3M | Form 4 |
| Jul 31, 2026 | Shan Riku SakakibaraChief Product Officer | Sold plan | 4,000 | $140.21 | $0.6M | Form 4 |
| Jul 16, 2026 | Nancy JoAnn JohnsonSee Remarks | Sold plan | 14,199 | $128.30 | $1.8M | Form 4 |
| Jul 13, 2026 | John Roderick ten BoschSVP of Laboratory Operations | Sold plan | 1,417 | $125.46 | $0.2M | Form 4 |
| Jul 13, 2026 | David TsaoChief Technology Officer, Director | Sold plan | 20,000 | $124.89 | $2.5M | Form 4 |
| Jul 9, 2026 | Shan Riku SakakibaraChief Product Officer | Sold plan | 8,000 | $125.00 | $1.0M | Form 4 |
| Jul 9, 2026 | Oguzhan AtayChairman and CEO, Director | Sold plan | 12,500 | $126.10 | $1.6M | Form 4 |
| Jul 6, 2026 | Oguzhan AtayChairman and CEO, Director | Sold plan | 35,410 | $122.13 | $4.3M | Form 4 |
| Jul 1, 2026 | Nancy JoAnn JohnsonSee Remarks | Sold plan | 801 | $124.91 | $0.1M | Form 4 |
| Jun 29, 2026 | John Roderick ten BoschSVP of Laboratory Operations | Sold plan | 1,416 | $120.00 | $0.2M | Form 4 |
| Jun 24, 2026 | Shan Riku SakakibaraChief Product Officer | Sold plan | 4,000 | $110.00 | $0.4M | Form 4 |
| Jun 15, 2026 | John Roderick ten BoschSee Remarks | Sold plan | 1,416 | $101.47 | $0.1M | Form 4 |
| Jun 15, 2026 | David TsaoChief Technology Officer, Director | Sold plan | 20,000 | $102.26 | $2.0M | Form 4 |
| Jun 9, 2026 | Nancy JoAnn JohnsonSee Remarks | Sold plan | 10,582 | $100.47 | $1.1M | Form 4 |
| Jun 8, 2026 | Oguzhan AtaySee Remarks, Director | Sold plan | 32,500 | $97.43 | $3.2M | Form 4 |
| Jun 8, 2026 | Shan Riku SakakibaraChief Product Officer | Sold plan | 8,000 | $98.23 | $0.8M | Form 4 |
| Jun 8, 2026 | Nancy JoAnn JohnsonSee Remarks | Sold plan | 3,418 | $99.29 | $0.3M | Form 4 |
| Nov 7, 2025 | Thomas S BremnerDirector | Bought | 41,666 | $60.00 | $2.5M | Form 4 |
| Nov 7, 2025 | Nancy JoAnn JohnsonSee Remarks | Bought | 6,900 | $60.00 | $0.4M | Form 4 |
| Nov 7, 2025 | Thomas P. LynchSee Remarks | Bought | 100 | $60.00 | $0.0M | Form 4 |
| Nov 7, 2025 | Akshay RaiDirector | Bought | 2,500 | $60.00 | $0.2M | Form 4 |
| Nov 7, 2025 | John Roderick ten BoschSee Remarks | Bought | 800 | $60.00 | $0.0M | Form 4 |
| Nov 7, 2025 | David TsaoChief Technology Officer, Director | Bought | 1,000 | $60.00 | $0.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· BillionToOne, Inc. has $438M more cash than debt.
Cash, debt and the ratios that show how comfortably BillionToOne, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $97.3M | $191M | $496M |
| Debt incl. finance leases | β | $51.5M | $58.1M |
| Net debt / EBITDA | β | β | β19.1x |
| Debt / equity | β | β | 0.1x |
| Interest coverage | β21.2x | β19.8x | 168.7x |
| Current ratio | β | 8.0x | 11.7x |
| Quick ratio | β | 7.7x | 11.3x |
| Total assets | β | $302M | $633M |
| Total liabilities | β | $134M | $153M |
| Shareholders' equity | β$219M | β$252M | $480M |
| Net debt (β = net cash) | β | β$140M | β$438M |
KIRA Β· Its return on capital was 37.2%: every 100 invested in the business earned about 37 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· BillionToOne, Inc. passes 7 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 3 | β / 5 | 7 / 9 |
| Accruals ratio | β | β0.1% | β3.7% |
| Altman Z'' | β | β1.73 | 7.37 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $71.7M | $153M | $305M |
| Gross profit | $17.3M | $80.9M | $208M |
| Research and development | $22.4M | $36.6M | $49.4M |
| Operating income | β$69.5M | β$47.1M | $16.0M |
| Interest expense | $3.3M | $2.4M | $0.1M |
| Pretax income | β$82.7M | β$41.5M | $7.8M |
| Income tax | $0.0M | $0.0M | $0.3M |
| Net income | β$82.7M | β$41.6M | $7.5M |
| Net income to common | β$82.7M | β$41.6M | $2.9M |
| Diluted EPS | β$8.45 | β$4.12 | $0.14 |
| Diluted shares | 0.01B | 0.01B | 0.02B |
| Cash flow | |||
| Cash from operations | β$53.7M | β$41.4M | $24.6M |
| Capital expenditure | $6.2M | $5.4M | $8.9M |
| Free cash flow | β$59.8M | β$46.8M | $15.7M |
| Depreciation and amortization | $5.9M | $7.0M | $6.9M |
| Stock-based compensation | $4.9M | $8.4M | $15.9M |
| Share buybacks | $0.0M | $0.5M | $0.0M |
| Dividends and buybacks | $0.0M | $0.5M | $0.0M |
| Balance sheet | |||
| Cash and short-term investments | $97.3M | $191M | $496M |
| Total debt | β | $51.5M | $57.2M |
| Finance lease liabilities | β | β | $0.9M |
| Current assets | β | $228M | $561M |
| Current liabilities | β | $28.4M | $48.0M |
| Inventory | β | $8.7M | $17.5M |
| Property and equipment, net | β | $17.1M | $20.4M |
| Total assets | β | $302M | $633M |
| Total liabilities | β | $134M | $153M |
| Shareholders' equity | β$219M | β$252M | $480M |
| Margins | |||
| Gross margin | 24.1% | 53.0% | 68.3% |
| Operating margin | β96.9% | β30.9% | 5.3% |
| EBITDA margin | β88.7% | β26.3% | 7.5% |
| Net margin | β115.3% | β27.2% | 2.4% |
| FCF margin | β83.4% | β30.7% | 5.2% |
| Returns | |||
| Return on capital | β | β | 37.2% |
| Return on capital employed | β | β17.2% | 2.7% |
| Return on equity | β | β | 6.5% |
| Return on assets | β | β13.8% | 1.6% |
| Return on tangible equity | β | β | 0.6% |
| Growth | |||
| Revenue growth | β | 112.7% | 100.0% |
| Share count change | β | 3.0% | 110.6% |
| Financial health | |||
| Net debt / EBITDA | β | β | β19.1x |
| Debt / equity | β | β | 0.1x |
| Interest coverage | β21.2x | β19.8x | 168.7x |
| Current ratio | β | 8.0x | 11.7x |
| Quick ratio | β | 7.7x | 11.3x |
| Capital allocation | |||
| Capex / revenue | 8.6% | 3.5% | 2.9% |
| Stock comp / revenue | 6.8% | 5.5% | 5.2% |
| Payouts / FCF | β | β | 0.0% |
| Quality scores | |||
| Piotroski F-score | β | β | 7.0 |
| Altman Z'' | β | β1.7 | 7.4 |
| Accruals ratio | β | β0.1% | β3.7% |
Source: SEC EDGAR XBRL filings (CIK 0002070849). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
